The effect of ticagrelor on the adenosine system

Completed

Conditions: forearm blood flow
10011082

Registration Number: NL-OMON38826

Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 14

Inclusion Criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- Male sex
- Age 18-40 years
- Healthy
- Written informed consent

Exclusion Criteria

A potential subject who meets any of the following criteria will be excluded from participation in this study:
- Smoking;
- Hypertension (Blood pressure >140 mmHg and/or >90 mmHg - SBP/DBP-)
- Diabetes Mellitus (fasting glucose > 7.0 mmol/L or random > 11.0 mmol/L);
- History of any cardiovascular disease
- History of chronic obstructive pulmonary disease (COPD) or asthma
- Bleeding tendency
- Concomitant use of medication
- Renal dysfunction (MDRD < 60 ml/min)
- Liver enzyme abnormalities (ALAT > twice upper limit of normality
- Thrombocytopenia (<150*109/ml)
- Second/third degree AV-block on electrocardiography

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Forearm blood flow response to the intrabrachial administration of adenosine<br /><br>and to 2 and 5 minutes of forearm ischemia (i.e. post-occlusive reactive<br /><br>hyperemia).</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Forearm blood flow response to the intrabrachial administration of<br /><br>dipyridamole.<br /><br>Transport characteristics of the ENT transporter, determined ex vivo on<br /><br>isolated erythrocytes.</p><br>